Call for Abstracts
Abstract Submission deadline: 3:00pm, September 20, 2019 (Japan Standard Time, UTC+9)
→ Extended to 3:00pm, September 27, 2019 (Japan Standard Time, UTC+9)
Call for Abstracts is now closed.
→ Extended to 3:00pm, September 27, 2019 (Japan Standard Time, UTC+9)
Call for Abstracts is now closed.
ABSTRACT SUBMISSION GUIDELINES
1. All abstract applicants are required to create a user account first. At a later date, you can register for this annual meeting with the account.
2. Once the submission is completed, you will receive automatically delivered e-mail confirming the receipt of your abstract. If you do not receive above e-mail within 24 hours after submission, please contact the Conference Secretariat (jshct2020@jtbcom.co.jp).
3. Abstract number will be generated automatically when an abstract is submitted. 4. For changes, withdrawal and additional submission of abstract, please log in with your ID and password by clicking "Abstract Submission" at the bottom of this page.
APPLICATION FOR GENERAL PRESENTATION (PAPER/POSTER)
1. SELECT THE DESIRED STYLE OF YOUR PRESENTATION
Submitted abstracts will be chosen for Oral presentation or Poster presentation depending on the results of peer review.
●ORAL PRESENTATION:
●ORAL PRESENTATION:
Computer-based presentation only (film slides or videotapes are not allowed)
●POSTER PRESENTATION:
Discussion in the Poster
2. SELECT AN APPROPRIATE CATEGORY FROM THE FOLLOWING LIST
| Main Category | Sub Category |
| 01. Stem Cell Biology | |
| 02. Histocompatibility Antigen | |
| 03. Stem Cell Mobilization and Collection | |
| 04. Transplant Source | |
| 05. Pretreatment | |
| 06. Supportive Therapy | |
| 07. Transplant Immunity | 07-1. Immune Reconstitution |
| 07-2. Acute GVHD | |
| 07-3. Chronic GVHD | |
| 07-4. GVL | |
| 07-5. Others | |
| 08. Immunotherapy/Cell Therapy | |
09. Child-specific Transplant Disease(Inborn errors of metabolism, Congenital immune deficiency and others) |
|
| 10. Transplant Outcomes | 10-1. Acute Leukemia |
10-2. Myelodysplastic Syndrome/Myeloproliferative Tumor |
|
| 10-3. Malignant Lymphoma/ATL | |
| 10-4. Multiple Myeloma/Plasma Cell Disorders | |
| 10-5. Aplastic Anemia | |
| 10-6. Others | |
| 11. Minimal Residual Disease and Recurrence | |
| 12. Early Complication | 12-1. Engraftment Failure |
| 12-2. TMA | |
| 12-3. VOD/SOS | |
| 12-4. Others | |
| 13. Late Complications | |
| 14. Infection | 14-1. Bacterial Infection |
| 14-2. Fungal Infection | |
| 14-3. Viral Infection | |
| 14-4. Others | |
| 15. Follow-up and QOL | |
16. Marrow Donor Program/Cord Blood Bank/Donors |
|
17. Hematopoietic Cell Transplant Coordinator and Coordinate |
|
| 18. Care | 18-1. Oral Care |
| 18-2. Skin Care | |
| 18-3. GVHD Care | |
| 18-4. Mental Care | |
| 18-5. Others | |
| 19. Management | 19-1. Infection Control |
| 19-2. Meal Management | |
| 19-3. Nutrition Management | |
| 19-4. Others | |
| 20. Rehabilitation | |
| 21. Nursing/Education | |
| 22. TDM/Drugs | |
| 23. Team Medical-care | |
GUIDELINES FOR ABSTRACT PREPARATION
1. The title should be no longer than 100 characters including spaces, affiliation should be concise and the abstract no longer than 1800 characters including spaces. In case you need to add one image(picture, chart, diagram) in your abstract, please reduce the word limitation to 900 characters.
2. The abstract should be structured with the following headings:,- Objective, Subjects and Methods, Results, and Conclusions, in that order. For case reports and invention or improvement of techniques and devices, the headings should be appropriately changed (for example, for case reports, Introduction, Cases, Discussion and, if relevant, Conclusions).
3. Presentations, abstracts and presentation data must be prepared in English.4. See below for declaration of conflict of interests.
5. On abstract submission form, please select whether you have obtained an approval of the ethics committee, e.g. IRB, or if it is not necessary. This does not need to be stated in the abstract text.
In the case that a presentation theme relates to “Ethical guidelines for Clinical Research”, the approval of the Institutional Review Board (IRB) or the Ethical Review Board (ERB) is required. Please refer to the guideline of the Ministry of Education, Culture, Sports, Science and Technology website.
CONFLICT OF INTEREST
1. When you submit an abstract, please report whether there are potential conflicts of interest with companies concerned with the content of your presentation within the last three years.
2. The authors(include co-authors) are required to disclose applicable COI by displaying a COI disclosure slide at the beginning of presentation slides (the slide after the title of presentation and the name of presenters) or at the end of a poster using samples as attached.
PERSONAL INFORMATION PROTECTION
"Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the “presenters' names," “affiliation names," “title" and “abstract text" shall be used for publication in the program/proceedings and on the website, but not for other purposes. The registration process for applications has been commissioned to c/o JTB Communication Design, Inc. in order to facilitate management operations
NOTIFICATION OF RECEIPT OF ABSTRACTS
For registration confirmation, notification will be sent to the registered e-mail address. If you do not receive notification at the registered e-mail address within 24 hours, please inform the conference secretariat.
All abstracts will be reviewed by the Program Committee, and the committee will make the final decision of acceptance/rejection. Authors will be notified by e-mail of peer review results and detailed information for their presentation.